All In Biotech

Free tool

FAERS Monitor: Mydayis

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022063 or its brand name (Mydayis, Amphetamine Aspartate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate). Reports on generic versions are filed under their own applications.

Reports

879

Serious

184

21% of reports

Hospitalization

36

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective219
  • fatigue61
  • insomnia57
  • headache53
  • anxiety49
  • off label use49
  • feeling abnormal47
  • product availability issue47
  • no adverse event46
  • inability to afford medication43
  • somnolence41
  • insurance issue39
  • nausea35
  • disturbance in attention31
  • depression30

Reports by year received

View as table
YearReports
201783
2018239
201997
202079
202195
202262
202381
202472
202540
202631

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,280 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
inability to afford medicationSignal43104.177.74,270
insurance issueSignal3961.245.02,245
product availability issueSignal4749.537.52,183
disturbance in attentionSignal3113.89.7355
no adverse eventSignal466.14.6192
insomniaSignal575.14.0187
somnolenceSignal414.93.6124
feeling abnormalSignal474.73.6134
anxietySignal494.13.1114
drug ineffectiveSignal2194.03.5517
depressionSignal303.22.242
headacheSignal532.01.627
fatigue611.91.525
off label use491.31.04
nausea351.10.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.